Health Care • Biotechnology: Pharmaceutical Preparations
$7.31 ▲ +0.02
(+0.27%)
MKT CAP: $1.61B • VOL: 2.21M
52W L $6 52W H $16
OCUL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $52.0M | $63.7M | $58.4M |
| YoY Revenue Growth % | -18.5% | +9.0% | — |
| Gross Profit | $45.4M | $58.1M | — |
| Gross Margin % | 87.3% | 91.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$270.0M | -$171.8M | -$82.4M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$265.9M | -$193.5M | -$80.7M |
| EBITDA (Normalized) | -$260.4M | -$170.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$204.9M | -$134.7M | -$70.2M |
| Capital Expenditures (CapEx) | $12.0M | $1.3M | — |
| Free Cash Flow (FCF) | -$216.9M | -$136.0M | -$70.2M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $737.1M | $392.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $654.3M | $315.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR OCUL.